These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 16723044

  • 21. Emerging mechanisms of molecular pathology in ALS.
    Peters OM, Ghasemi M, Brown RH.
    J Clin Invest; 2015 May; 125(5):1767-79. PubMed ID: 25932674
    [Abstract] [Full Text] [Related]

  • 22. [Superoxide dismutase-1 (SOD-1) gene mutation-dependent mechanisms of neural degeneration in amyotrophic lateral sclerosis].
    Iłzecka J.
    Neurol Neurochir Pol; 2001 May; 35(3):461-9. PubMed ID: 11732268
    [Abstract] [Full Text] [Related]

  • 23. Pharmacological treatment of ALS.
    Münch C, Ludolph AC.
    Neurol Neurochir Pol; 2001 May; 35(1 Suppl):41-50. PubMed ID: 11732279
    [Abstract] [Full Text] [Related]

  • 24. Depletion of reduced glutathione enhances motor neuron degeneration in vitro and in vivo.
    Chi L, Ke Y, Luo C, Gozal D, Liu R.
    Neuroscience; 2007 Feb 09; 144(3):991-1003. PubMed ID: 17150307
    [Abstract] [Full Text] [Related]

  • 25. Therapeutic targeting of epigenetic components in amyotrophic lateral sclerosis (ALS).
    Lee J, Ryu H, Keum G, Yoon YJ, Kowall NW, Ryu H.
    Curr Med Chem; 2014 Feb 09; 21(31):3576-82. PubMed ID: 25005187
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Current developments in gene therapy for amyotrophic lateral sclerosis.
    Scarrott JM, Herranz-Martín S, Alrafiah AR, Shaw PJ, Azzouz M.
    Expert Opin Biol Ther; 2015 Jul 09; 15(7):935-47. PubMed ID: 25959569
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis.
    Andreassen OA, Ferrante RJ, Klivenyi P, Klein AM, Shinobu LA, Epstein CJ, Beal MF.
    Ann Neurol; 2000 Apr 09; 47(4):447-55. PubMed ID: 10762155
    [Abstract] [Full Text] [Related]

  • 31. Therapeutic advances in amyotrophic lateral sclerosis.
    Louvel E, Hugon J, Doble A.
    Trends Pharmacol Sci; 1997 Jun 09; 18(6):196-203. PubMed ID: 9226998
    [Abstract] [Full Text] [Related]

  • 32. Superoxide dismutase and neurofilament transgenic models of amyotrophic lateral sclerosis.
    Morrison BM, Morrison JH, Gordon JW.
    J Exp Zool; 1997 Jun 09; 282(1-2):32-47. PubMed ID: 9723164
    [Abstract] [Full Text] [Related]

  • 33. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues.
    Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, Rothstein JD.
    Neurobiol Dis; 2001 Dec 09; 8(6):933-41. PubMed ID: 11741389
    [Abstract] [Full Text] [Related]

  • 34. [Physiopathology of ALS: therapeutic approach].
    Bruneteau G, Demeret S, Meininger V.
    Rev Neurol (Paris); 2004 Feb 09; 160(2):235-41. PubMed ID: 15034483
    [Abstract] [Full Text] [Related]

  • 35. Recent advances in amyotrophic lateral sclerosis.
    Al-Chalabi A, Leigh PN.
    Curr Opin Neurol; 2000 Aug 09; 13(4):397-405. PubMed ID: 10970056
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Amyotrophic lateral sclerosis.
    Rowland LP, Shneider NA.
    N Engl J Med; 2001 May 31; 344(22):1688-700. PubMed ID: 11386269
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.